ReviewChemical science2026
Artificial recombinant high-density protein nanocarriers for precision drug delivery.
Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High-density lipoprotein (HDL) is a naturally occurring nanoparticle characterized by excellent biocompatibility and intrinsic receptor-mediated targeting capabilities. Consequently, recombinant high-density lipoprotein (rHDL) has emerged as a highly promising platform for precision drug delivery. This review focuses on the latest advancements in rHDL design, highlighting how key parameters-such as the stoichiometry of lipids to proteins, the engineering of apolipoproteins or mimetic peptides, and interfacial functionalization-govern the nanoparticle's structure, payload integration, and biological performance. We specifically demonstrate how these design principles enable the precise and tunable control of particle size, stability, and targeting efficiency across diverse therapeutic applications, including oncology, atherosclerosis, and neurodegenerative diseases. Compared to conventional nanocarriers, rHDL exhibits distinct advantages by virtue of its biomimetic properties and receptor-specific delivery pathways. In summary, these collective advancements establish rHDL as a "chemically programmable" nanoplatform, underscoring its immense potential to drive the development of targeted and multifunctional therapeutics.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.